Literature DB >> 18978964

Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Jay Jagannathan1, Rod J Oskouian, Hian Kwang Yeoh, Dwight Saulle, Aaron S Dumont.   

Abstract

Even though meningiomas are most often benign tumors, they can be locally invasive and can develop in locations that prevent surgical treatment. The molecular and biologic factors underlying meningioma development are only now beginning to be understood. Genetic factors such as mutations in the neurofibromatosis-2 gene and in chromosomes 1, 9, and 10 play important roles in meningioma development and may be responsible for atypical tumors in some cases. Cellular factors such as telomerase activation and tyrosine kinase receptor mutations may also play an important role. Finally, autocrine and paracrine factors including epidermal growth factor receptor, platelet-derived growth factor-1, and fibroblast growth factor have been implicated in the development of some tumors. Although the relationship between the various factors implicated in tumor development is unknown, understanding these factors will be critical in the treatment of malignant or surgically inaccessible tumors.

Entities:  

Keywords:  Aggressive; atypical; biology; meningioma; treatment

Year:  2008        PMID: 18978964      PMCID: PMC2459329          DOI: 10.1055/s-2007-1003925

Source DB:  PubMed          Journal:  Skull Base        ISSN: 1531-5010


  120 in total

1.  Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas.

Authors:  P Leuraud; Y Marie; E Robin; S Huguet; J He; K Mokhtari; P Cornu; K Hoang-Xuan; M Sanson
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Cytological and cytogenetical studies on brain tumors. 3. Ph1-like chromosomes in human meningiomas.

Authors:  H Zankl; K D Zang
Journal:  Humangenetik       Date:  1971

3.  Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.

Authors:  E Cabuy; L de Ridder
Journal:  Virchows Arch       Date:  2001-08       Impact factor: 4.064

4.  Progesterone and estrogen receptors in meningiomas: prognostic considerations.

Authors:  D W Hsu; J T Efird; E T Hedley-Whyte
Journal:  J Neurosurg       Date:  1997-01       Impact factor: 5.115

5.  A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.

Authors:  Arie Perry; Ruma Banerjee; Christine M Lohse; Bette K Kleinschmidt-DeMasters; Bernd W Scheithauer
Journal:  Brain Pathol       Date:  2002-04       Impact factor: 6.508

6.  Enhanced expression of the sis and c-myc oncogenes in human meningiomas.

Authors:  K Kazumoto; M Tamura; H Hoshino; Y Yuasa
Journal:  J Neurosurg       Date:  1990-05       Impact factor: 5.115

7.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

8.  Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.

Authors:  Dana Mihaila; Michelle Jankowski; Jorge A Gutiérrez; Mark L Rosenblum; Irene F Newsham; Oliver Bögler; Sandra A Rempel
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

9.  Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells.

Authors:  Z J Zhang; C Muhr; J L Wang
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

10.  Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.

Authors:  Clemens M F Dirven; Jacques Grill; Martine L M Lamfers; Paul Van der Valk; Angelique M Leonhart; Victor W Van Beusechem; Hidde J Haisma; Herbert M Pinedo; David T Curiel; W Peter Vandertop; Winald R Gerritsen
Journal:  J Neurosurg       Date:  2002-08       Impact factor: 5.115

View more
  6 in total

1.  What are the hallmarks of cancer?

Authors:  Yuri Lazebnik
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

2.  Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.

Authors:  Xu Zhang; Haiying Jia; Yao Lu; Chengliang Dong; Jinghui Hou; Zheng Wang; Feng Wang; Hongbin Zhong; Lin Wang; Kai Wang
Journal:  Discov Med       Date:  2014-12       Impact factor: 2.970

Review 3.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

4.  The potential involvement of E-cadherin and beta-catenins in meningioma.

Authors:  Keiyu Zhou; Guangtao Wang; Yirong Wang; Hanghuang Jin; Shuxu Yang; Chibo Liu
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

5.  Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study.

Authors:  Rehab Allah Ahmed; Abdelhadi M Shebl; Hany Onsy Habashy
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

Review 6.  Emerging Medical Treatments for Meningioma in the Molecular Era.

Authors:  Fares Nigim; Hiroaki Wakimoto; Ekkehard M Kasper; Linda Ackermans; Yasin Temel
Journal:  Biomedicines       Date:  2018-08-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.